PRESS RELEASE

In accordance with a decision made by the Annual General Meeting held on May 26, 2016, the Election Committee shall comprise the representatives for the three largest shareholders, as per end of September 2016, and the Chairman of the Board.

For the 2017 Annual General Meeting, the Election Committee shall propose Board members and a Chairman of the Board, and fees to Board members and auditors. The following individuals were appointed representatives for the largest shareholders and, accordingly, are members of the Election Committee:

Johnny Sommarlund, MGA Holding
Tomas Billing, Nordstjernan
Lennart Johansson, Investor

Under the leadership of the Chairman of the Board, Mats Arnhög, the Election Committee shall prepare proposals to be presented to and decided upon at the Annual General Meeting on June 15 2017.

Lund, November 22, 2016
Active Biotech AB (publ)

Tomas Leanderson
President and CEO

Active Biotech AB (publ) (NASDAQ Stockholm: ACTI) is a biotechnology company with focus on neurodegenerative/inflammatory diseases and cancer. Laquinimod, an orally administered small molecule with unique immunomodulatory properties, is in pivotal Phase 3 development for the treatment of relapsing remitting multiple sclerosis. Also, laquinimod is in Phase 2 development for the treatment of primary progressive multiple sclerosis and Huntington's disease. Furthermore, commercial activities are conducted for the tasquinimod, paquinimod och SILC projects. Please visit www.activebiotech.com for more information.

Active Biotech AB
(Corp. Reg. No. 556223-9227)
Box 724, SE-220 07 Lund, Sweden
Tel: +46 (0)46 19 20 00